FAM21EP: A Potential Drug Target and Biomarker (G100421577)

Target Name: FAM21EP

NCBI ID: G100421577

FAM21EP

Other Name(s): FAM21B pseudogene | Family with sequence similarity 21, member A pseudogene | family with sequence similarity 21 member E, pseudogene

FAM21EP: A Potential Drug Target and Biomarker

FAM21EP is a gene that encodes a protein known as FAM21-related protein (FAM21R), which is a key regulator of the sprouting angiogenesis pathway. This pathway is a critical component of the development and maintenance of tissues and organs, including blood vessels, and is involved in the formation of new blood vessels and the regulation of blood flow.

FAM21R plays a crucial role in the sprouting angiogenesis pathway by regulating the formation of new blood vessels and the growth of existing blood vessels. It does this by interacting with several other genes, including the transcription factor, NF-kappa-B, and the Wnt gene.

The sprouting angiogenesis pathway is a critical component of the development and maintenance of tissues and organs, including blood vessels. It is involved in the formation of new blood vessels and the regulation of blood flow, and is closely involved in the development of new tissues and organs.

FAM21R is a key regulator of the sprouting angiogenesis pathway, and its function is essential for the proper development and maintenance of tissues and organs. It is possible that FAM21R may be a drug target, or it may be a biomarker for the diagnosis and treatment of diseases associated with sprouting angiogenesis pathway disorders.

FAM21R is a transmembrane protein that is expressed in a variety of tissues and organs, including blood vessels, heart, and kidneys. It is involved in the regulation of the sprouting angiogenesis pathway, and is thought to play a key role in the formation of new blood vessels and the growth of existing blood vessels.

The sprouting angiogenesis pathway is a critical component of the development and maintenance of tissues and organs, including blood vessels. It is involved in the formation of new blood vessels and the regulation of blood flow, and is closely involved in the development of new tissues and organs.

FAM21R is a key regulator of the sprouting angiogenesis pathway, and its function is essential for the proper development and maintenance of tissues and organs. It is possible that FAM21R may be a drug target, or it may be a biomarker for the diagnosis and treatment of diseases associated with sprouting angiogenesis pathway disorders.

If FAM21R is a drug target, it is likely that a drug that inhibits its activity or blocks its formation could be effective in treating a variety of diseases associated with sprouting angiogenesis pathway disorders. These diseases may include heart disease, stroke, and various forms of cancer.

FAM21R is also a potential biomarker for the diagnosis and treatment of diseases associated with sprouting angiogenesis pathway disorders. By measuring the level of FAM21R in tissues and fluids, doctors may be able to determine the effectiveness of a drug or other treatment in treating these diseases.

Overall, FAM21R is a gene that is involved in the sprouting angiogenesis pathway and may be a drug target or biomarker for the diagnosis and treatment of diseases associated with this pathway. Further research is needed to fully understand its function and potential as a drug.

Protein Name: Family With Sequence Similarity 21 Member E, Pseudogene

The "FAM21EP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM21EP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets